A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 23, Issue 2, 2007, Pages 116-119

  Herrmann, Nathan ^a,b,c   Lanctôt, Krista L ^a,b,c   Rothenburg, Lana S ^a   Eryavec, Goran ^b,c,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NORTH YORK GENERAL HOSPITAL   (Canada)

Author keywords

Aggression; Agitation; Alzheimer's disease; Valproate

Indexed keywords

LOXAPINE; PLACEBO; VALPROIC ACID;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; FALLING; FEMALE; HUMAN; LOOSE FECES; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; AGGRESSION; ALZHEIMER DISEASE; ANTICONVULSANTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSTITUTIONALIZATION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; SEVERITY OF ILLNESS INDEX; VALPROIC ACID;

EID: 33846218161     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097757     Document Type: Article

References (23)

1. Finkel S: Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 2000;15(suppl 1):S2-S4.
2. Marx MS, Cohen-Mansfield J, Werner P: Agitation and falls in institutionalized elderly persons. J Appl Gerontol 1990;9:106-117.
3. Evans LK, Strumpf NE: Tying down the elderly. A review of the literature on physical restraint. J Am Geriatr Soc 1989;37:65-74.
4. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST: Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999;56:1266-1272.
5. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC: Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol 1997;54:878-885.
6. Keene J, Hope T, Fairburn CG, Jacoby R, Gedling K, Ware CJ: Natural history of aggressive behaviour in dementia. Int J Geriatr Psychiatry 1999;14:541-548.
7. Herrmann N, Lanctôt KL, Sambrook R, Lesnikova N, Hebert R, McCracken P, Robillard A, Nguyen E: The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 2006;21:972-976.
8. Herrmann N, Lanctôt KL: Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
9. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943.
10. Herrmann N: Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001;28(suppl 1):S96-S107.
11. Tariot PN, Schneider LS, Mintzer JE, Cutler AJ: Safety and tolerability of divalproex sodium in treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind placebo-controlled trial. Curr Ther Res Clin Exp 2001;62:51-67.
12. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C: Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58-66.
13. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P: Sodium valproate in the treatment of aggressive behavior in patients with dementia - A randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002;17:579-585.
14. Lonergan ET, Cameron M, Luxenberg J: Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2004;2:CD003945.
15. Folstein MF, Folstein SE, McHugh PR: 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
17. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
18. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly. 1. A conceptual review. J Am Geriatr Soc 1986;34:711-721.
19. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L: Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005;13:942-949.
20. Lanctôt KL, Herrmann N, Rothenburg L, Eryavec GM: Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int Psychogeriatr 2006, published online.
21. Lanctôt KL, Herrmann N, Mazzotta P, Khan LR, Ingber N: GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004;49:439-453.
22. Trannel TJ, Ahmed I, Goebert D: Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry 2001;158:128-130.
23. Sival RC, Duivenvoorden HJ, Jansen PA, Haffmans PM, Duursma SA, Eikelenboom P: Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. Int J Geriatr Psychiatry 2004;19:305-312.